C Xiang, Y Yan, D Zhang - Journal of pharmacological sciences, 2021 - Elsevier
Objective Treatment with the chemotherapeutic agent, doxorubicin (DOX), is limited by side
effects. We have previously demonstrated that fasudil, a Rho/ROCK inhibitor, has …